High-throughput screening: Update on practices and success
High-throughput screening: Update on practices and success
复制标题
DOI：
10.1177/1087057106292473
复制
发表时间：
2006-10-01
影响因子：
--
通讯作者：
Biros, Michael
中科院分区：
文献类型：
--
作者：
Fox, Sandra;Farr-Jones, Shauna;Biros, Michael
高通量筛选已成为世界上大多数制药公司和许多生物技术公司药物发现的重要组成部分，高通量筛选技术的应用正在向新的领域扩展。靶标验证、分析开发、二次筛选、ADME/Tox和先导物优化是HTS技术越来越多使用的领域之一。它正在与上游和下游的药物发现完全整合，其中包括越来越多地使用基于细胞的测定和高含量筛选（HCS）技术，以获得更多生理学相关的结果并找到更高质量的线索。此外，HTS实验室在努力提高寻找候选药物的成功率的同时，也在不断地评估新技术。本文中的材料基于一份900页的HTS行业报告，涉及代表58个HTS实验室和34个供应商的54名HTS董事。
High-throughput screening (HTS) has become an important part of drug discovery at most phannaceutical and many biotechnology companies worldwide, and use of HTS technologies is expanding into new areas. Target validation, assay development, secondary screening, ADME/Tox, and lead optimization are among the areas in which there is an increasing use of HTS technologies. It is becoming fully integrated within drug discovery, both upstream and downstream, which includes increasing use of cell-based assays and high-content screening (HCS) technologies to achieve more physiologically relevant results and to find higher quality leads. In addition, HTS laboratories are continually evaluating new technologies as they struggle to increase their success rate for finding drug candidates. The material in this article is based on a 900-page HTS industry report involving 54 HTS directors representing 58 HTS laboratories and 34 suppliers.